Science and Research

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting

Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) levels, decreased SLC35F2 (mediates YM155 uptake) levels, decreased survivin levels, and TP53 mutations indicate YM155 resistance. Here, the investigation of 10 additional YM155-adapted UKF-NB-3 sublines only confirmed the roles of ABCB1 and SLC35F2. However, cellular ABCB1 and SLC35F2 levels did not indicate YM155 sensitivity in YM155-naive cells, as indicated by drug response data derived from the Cancer Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer (GDSC) databases. Moreover, the resistant sublines were characterized by a remarkable heterogeneity. Only seven sublines developed on-target resistance as indicated by resistance to RNAi-mediated survivin depletion. The sublines also varied in their response to other anti-cancer drugs. In conclusion, cancer cell populations of limited intrinsic heterogeneity can develop various resistance phenotypes in response to treatment. Therefore, individualized therapies will require monitoring of cancer cell evolution in response to treatment. Moreover, biomarkers can indicate resistance formation in the acquired resistance setting, even when they are not predictive in the intrinsic resistance setting.

  • Michaelis, M.
  • Wass, M. N.
  • Reddin, I.
  • Voges, Y.
  • Rothweiler, F.
  • Hehlgans, S.
  • Cinatl, J.
  • Mernberger, M.
  • Nist, A.
  • Stiewe, T.
  • Rodel, F.
  • Cinatl, J., Jr.

Keywords

  • Birc5
  • acquired drug resistance
  • biomarkers
  • intrinsic drug resistance
  • neuroblastoma
  • survivin
  • therapy monitoring
  • design of the study
  • in the collection, analyses, or interpretation of data
  • in
  • the writing of the manuscript, or in the decision to publish the results.
Publication details
DOI: 10.3390/cancers12051080
Journal: Cancers (Basel)
Number: 5
Work Type: Original
Location: UGMLC
Disease Area: LC
Partner / Member: UMR
Access-Number: 32357518
See publication on PubMed

DZL Engagements

chevron-down